Zacks Investment Research upgraded shares of Xoma Corp. (NASDAQ:XOMA) from a hold rating to a buy rating in a research note published on Wednesday. Zacks Investment Research currently has $6.00 price target on the stock.
According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “
Other equities research analysts also recently issued research reports about the stock. Jefferies Group reaffirmed a hold rating on shares of Xoma Corp. in a research report on Friday, August 5th. Cowen and Company reaffirmed a market perform rating on shares of Xoma Corp. in a research report on Monday, September 19th. Finally, Wedbush reaffirmed an outperform rating and issued a $17.00 target price on shares of Xoma Corp. in a research report on Wednesday, October 19th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $5.66.
Shares of Xoma Corp. (NASDAQ:XOMA) opened at 5.51 on Wednesday. Xoma Corp. has a 12 month low of $4.70 and a 12 month high of $40.60. The stock has a market cap of $33.22 million, a P/E ratio of 24.38 and a beta of 2.87. The company has a 50 day moving average price of $1.75 and a 200-day moving average price of $0.93.
Xoma Corp. (NASDAQ:XOMA) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.01. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.84 million. During the same period in the previous year, the business posted ($0.20) earnings per share. On average, equities research analysts predict that Xoma Corp. will post ($9.30) earnings per share for the current year.
Large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Xoma Corp. by 19.6% in the second quarter. Vanguard Group Inc. now owns 5,321,901 shares of the company’s stock valued at $2,934,000 after buying an additional 871,594 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Xoma Corp. during the first quarter valued at $374,000. Paloma Partners Management Co purchased a new position in shares of Xoma Corp. during the second quarter valued at $185,000. Bellevue Group AG purchased a new position in shares of Xoma Corp. during the first quarter valued at $174,000. Finally, Spark Investment Management LLC increased its position in shares of Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock valued at $112,000 after buying an additional 102,400 shares in the last quarter.
About Xoma Corp.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.